GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-programmed death (PD)-1, versus investigator's choice (IC) chemotherapy in >= 2 line recurrent or metastatic cervical cancer